Mentari leans on about $50M related-party loan as losses reach $63M
Unaudited filings show Mentari burning through cash this year, with affiliated lending covering much of the gap and an accounting entry hinting at a possible share sale.
Mentari Therapeutics lost $63.0 million over the first nine months of 2026, according to unaudited financial statements published through InMed Pharmaceuticals Inc. The third quarter accounted for $32.2 million of that, meaning roughly half of the nine-month deficit was incurred in the latest three months.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): InMed Pharmaceuticals Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.